Quote | Coherus BioSciences Inc. (NASDAQ:CHRS)
|Last Trade Date Time:||12/01/2023 03:00:00 am|
News | Coherus BioSciences Inc. (NASDAQ:CHRS)
2023-12-01 10:17:15 ET The UBS pharma equity team is out with a quant list of most crowded stocks on the long and short side. Crowding is a sentiment metric that basically measure popularity in positioning (long or short). It indicates if a stock has a significantly above-average number...
2023-11-28 13:35:38 ET More on Coherus BioSciences Coherus BioSciences Is A Buy On The Dip After Toripalimib Approval Coherus: The Surface Acquisition Is A Distraction Coherus BioSciences, Inc. (CHRS) Q3 2023 Earnings Call Transcript Coherus stock rises as Ba...
Message Board Posts | Coherus BioSciences Inc. (NASDAQ:CHRS)
|MomentumIts gaining last up||DewDiligence||investorshub||05/09/2023 8:42:13 PM|
|$CHRS good read||DewDiligence||investorshub||05/08/2023 4:47:45 PM|
|short data if anyone is interested||dinogreeves||investorshub||05/08/2023 11:07:14 AM|
|should we be shorting?||DewDiligence||investorshub||05/08/2023 6:16:37 AM|
|$CHRS must see||dinogreeves||investorshub||05/08/2023 5:57:13 AM|
News, Short Squeeze, Breakout and More Instantly...
Coherus BioSciences Inc. Company Name:
CHRS Stock Symbol:
Coherus BioSciences Inc. Website:
– Final overall survival analysis of the JUPITER-02 trial shows first-line treatment with LOQTORZI plus chemotherapy significantly prolongs survival in patients with recurrent or metastatic NPC irrespective of PDL-1 status– – Treatment resulted in a 37% reduction in...
2023-11-10 15:15:37 ET A disappointing quarter combined with a set of analyst price target cuts -- and even a recommendation downgrade -- made Coherus BioSciences (NASDAQ: CHRS) a stock to avoid this week. As of mid-afternoon Friday, according to data compiled by S&P Global Ma...
Key Takeaways: Junshi Bio will receive milestone payments and 20% of sales of its PD-1 drug Toripalimab in the U.S., following the drug’s re...